STOCK TITAN

Thorne Healthtech, Inc. - THRN STOCK NEWS

Welcome to our dedicated page for Thorne Healthtech news (Ticker: THRN), a resource for investors and traders seeking the latest updates and insights on Thorne Healthtech stock.

Thorne HealthTech, Inc. (NASDAQ: THRN) delivers science-backed wellness solutions through innovative health technologies and nutritional products. This dedicated news hub provides investors and health enthusiasts with essential updates about the company's market position, research advancements, and strategic developments.

Access timely reports on earnings announcements, product innovations, and partnership milestones. Stay informed about Thorne's industry-leading collaborations with medical institutions and professional sports organizations. Our curated news collection simplifies tracking regulatory filings, leadership updates, and consumer health trends impacting the company.

Key updates include progress on Thorne's exclusive Mayo Clinic research partnership, expansion of at-home testing solutions, and strategic business developments. The resource serves investors analyzing market performance and healthcare professionals monitoring evidence-based wellness solutions.

Bookmark this page for streamlined access to official press releases and third-party analysis. Check regularly for updates on Thorne's mission to advance personalized healthcare through cutting-edge biomarker technology and nutritional science.

Rhea-AI Summary
L Catterton successfully completes acquisition of Thorne HealthTech, Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
L Catterton and Thorne HealthTech, Inc. announced the expiration of the tender offer to purchase all shares of Thorne's common stock. 97.3% of the shares were tendered and not withdrawn, satisfying all conditions of the offer. The acquisition is expected to be completed on October 16, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
none
-
Rhea-AI Summary
L Catterton to acquire Thorne HealthTech for $10.20 per share in cash, representing a 94% premium to the unaffected price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.19%
Tags
Rhea-AI Summary
Thorne HealthTech, Inc. (NASDAQ: THRN) reports a 33.1% increase in net sales to $72.7 million and a 35.7% growth in gross profit to $40.6 million for the second quarter of 2023. The company also raised its full-year guidance for net sales and gross margin, with updated ranges of $285 million to $290 million for net sales and 50% to 52% for gross profit as a % of net sales. Thorne HealthTech achieved a net income of $4.4 million and adjusted EBITDA of $12.5 million, leading to a diluted EPS of $0.08 and adjusted diluted EPS of $0.15. Additionally, the company earned CE Mark certification for its at-home blood sampling device in the European Union.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.82%
Tags
-
Rhea-AI Summary
Thorne HealthTech, Inc. (NASDAQ: THRN) will release its second quarter 2023 financial results on Aug. 8, 2023. The company will host a conference call to discuss the results on the same day at 5:00 p.m. (U.S. Eastern Time). Thorne HealthTech has withdrawn its participation in the Canaccord Genuity 43rd Annual Growth Conference on Aug. 10, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.59%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
conferences
Rhea-AI Summary
Thorne HealthTech, Inc. (NASDAQ: THRN) announces its Build to Last campaign, featuring Dwyane Wade and his son Zaire, highlighting the company's commitment to innovative, high-quality, personalized health and wellness products. The campaign emphasizes the Wades' partnership with Thorne to share their wellness journey and promote Thorne's suite of premium nutritional supplements. Thorne's comprehensive approach to health and wellness is rooted in personalization and scientific rigor, empowering consumers to make choices to optimize their health at every age and life stage.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.19%
Tags
none
-
Rhea-AI Summary
Thorne HealthTech's NanoDrop device receives CE Mark certification, expanding the company's line of innovative health-care solutions. The device allows individuals to collect capillary whole-blood samples at home, making it suitable for decentralized clinical trials and at-home diagnostic testing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.51%
Tags
partnership
Thorne Healthtech, Inc.

Nasdaq:THRN

THRN Rankings

THRN Stock Data

550.63M
14.30M
73.8%
10.28%
0.52%
Packaged Foods
Consumer Defensive
Link
United States
New York